Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RADIO: Dolutegravir PK with Rifampicin
NCT03199690Phase 1Unknown
- Sponsor
- St Stephen's Clinical Research
- Start
- Oct 2017
- Primary completion
- Mar 2018
- Modality
- Small Molecules
01
Overview
Phase 1, open-label, single-arm trial of dolutegravir in human immunodeficiency virus type 1 infection (HIV-1), sponsored by St Stephen's Clinical Research. Primary endpoints: Trough Concentration at 43 days, Maximum Observed Plasma Concentration at 43 days and 3 more. Status: unknown.
02
Drugs
dolutegravir
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT03199690.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03199690.